Fina Biosolutions is looking forward to attending BIO International Convention in a few weeks. Andrew and team will be in San Diego and are always open to making new connections and sharing how Fina BioSolutions LLC's conjugate vaccine expertise can advance your vaccine. We have our expanded portfolio of vaccine carrier proteins including CRM197, site specific CRM197 and the first genetically detoxified full-length tetanus toxin. We love to talk conjugation! #FinaXpress, our E coli platform for difficult to express proteins, is also on the BIO menu. From malaria antigens to cytokines, the FinaXpress platform can express soluble, disulfide bond proteins in the cytoplasm at high yield, without the need for refolding. FinaXpress has a few new tricks, too. We look forward to speaking with you. The BIO One-on-One Partnering System is now open for booking meetings with us. Attending BIO 2024? Click below to send Fina Biosolutions, LLC a meeting request in the BIO partnering system! #BIO2024 https://lnkd.in/gZ6rTSx3 Looking forward to exploring potential collaborations! About BIO International Convention: The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe. Whether you work at a public pharmaceutical company, biotech startup, academia, non-profits, and government or are a researcher, business development professional or investor, BIO is where you'll make valuable connections and build relationships. At BIO 2024, where issues & insights converge, you can access more than 100 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators, and patient advocates committed to ground-breaking therapies and innovation. June 3-6, 2024 - San Diego Convention Center, California #biotechinnovation #biotech #networking #Collaboration #partners #vaccineinnovation #biotechnology #startups #RnD #biomanufacturing #biopharma #BIO #innovation #conjugatevaccine #Ecoli #FinaBio #CRM197
Fina BioSolutions LLC
Biotechnology Research
Rockville, MARYLAND 545 followers
Conjugate Vaccine Research & Development, Carrier Proteins, CRM197
About us
Fina Biosolutions LLC is a privately held research and development stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorix™ Menitorix™, Nimenrix™, The Serum Institute of India Ltd., The Chengdu Institute of Biological Products and others. Fina Bosolutions also manufactures E. coli expressed CRM197 conjugate vaccine carrier portein. Fina BioSolutions also develops polymer based diagnostic reagents, amino dextran, and antibody dextran conjugates.
- Website
-
http://www.finabio.com
External link for Fina BioSolutions LLC
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Rockville, MARYLAND
- Type
- Privately Held
- Founded
- 2006
- Specialties
- Conjugate vaccines, Bioconjugation, Protein Purification, Amino Dextran, Antibody Dextran Conjugates, and CRM197
Locations
-
Get directions
9430 Key West Ave suite 200
STE 200
Rockville, MARYLAND 20850, US
Employees at Fina BioSolutions LLC
Updates
-
4 days to go! Next week we will be at #WVC2024 in Washington. Come visit us at Booth 542 or reach out to book a meeting if you would like to learn more about what Fina BioSolutions LLC is working on to advance vaccine access & affordability! About World Vaccine Congress Washington: R&D + Strategic Partnering for the Global Vaccine Industry The conference will cover Clinical Development, Bioprocessing & Manufacturing, Cancer Immunotherapy and much more. The exhibition will include 250+ leading solution providers from across the globe, featuring new ways of thinking and novel partnerships to generate solutions. Networking is at the heart of World Vaccine Congress Washington. The congress allows you to connect directly with thousands of vaccine experts across 4 days of built-in 1-2-1 networking. The Start-to-Finish of Vaccines From research, immune profiling & clinical trials to manufacture and access. https://lnkd.in/ewHGcf3 April 1, 2024 | Pre-Congress Workshops April 2 - 4, 2024 | Main Congress Days WALTER E CONVENTION CENTER, WASHINGTON D.C. #WVC2024 #Biotechinnovation #Biotech #biotechnology #vaccineinnovation #vaccinedevelopment #vaccineresearch #networking #collaboration #partnership #innovation #vaccines #drugdelivery #noveldrugs #vaccineplatforms #conjugatevaccines #conjugation #EcoCRM #FinaXpress #Finabio
Fina Biosolutions will be at the World Vaccine Congress DC April 1-4. We are introducing MonoClickCRM. This site-specific tetrazine CRM197 is the newest protein in FinaBio's "Ready-to-Conjugate" carrier protein collection. FinaBio's collection of carrier proteins includes EcoCRM® (CRM197, R&D & GMP), 8MTT(tetanus), rTTHc, and Qbeta (VLP). Visit FinaBio booth 542. I look forward to meeting new and old friends at #WVC #FinaBio, #CRM197, #EcoCRM
-
-
Fina BioSolutions LLC reposted this
Very proud to receive, in person, the Am Chem Soc Horton Award for for "Outstanding Contributions to Industrial Carbohydrate Chemistry" in New Orleans last week. Peter Andreanna (U Toledo) introduced me, and each of us gave a symposium talk. Also presenting the award was Clay Bennet (Tufts). The award was for my development of CDAP chemistry for efficient polysaccharide conjugation. Also noted were my efforts to promote affordable conjugate vaccines, including the development of EcoCRM®(CRM197). Very conveniently, Dr. Andreanna left open the screen showing my National Geographic Kids "Biography" showing my progression from graduate school magician to biotech CEO. #ACSCARB, #FinaBio, #CDAP, #conjugatevaccine, #EcoCRM, #CRM197, #Milkthisaward
-
-
We are looking forward to making new connections at #wvcdc! Reach out if you would like to book a meeting or come visit us at Stand 542 to connect and learn more about our solutions for vaccine development & manufacturing. #biotechinnovation #biotechindustry #wvc2024 #vaccines #vaccinedevelopment #vaccineresearch #innovate #collaboration #networking #partnership
Mark your calendars for the World Vaccine Congress Washington 2024 on April 1-4 in D.C. Visit our booth to see how Fina Biosolutions is contributing to the future of vaccination. We are introducing new carrier proteins for conjugate vaccines. Register today! https://lnkd.in/esuyQ9zM #WVCDC #WorldVaccineCongress
-
A huge congratulations to our founder Andrew Lees, Ph.D. on his award recognizing CDAP conjugation discoveries that ultimately led to the launch of Fina BioSolutions LLC as a company focused on providing conjugate vaccine components to developers around the world. #vaccines #cdap #vaccinedevelopment #vaccineresearch #biotechinnovation #lifesciences #biotech #biotechnology
The American Chemical Society CARB division has recognized ne for my introduction of CDAP conjugation chemistry and efforts to make conjugate vaccines more affordable. I will be receiving the Horton Award for Outstanding Contributions to Industrial Carbohydrate Chemistry at the March ACS meeting in New Orleans. CDAP chemistry changed my scientific life and has been a major contribution to the field. (This is not a humblebrag. It is an outright brag 😀. Also note that this is an old picture & I have a lot more grey hares now) #CDAP, #FinaBio, #ACS, #ACSCarb, #NewOreans, #conjugation
-
-
Looking forward to connecting with others advancing vaccine development at #wvc2024! #vaccinedevelopment #finabio #vaccines
Please join Scorpius BioManufacturing, Inc. and Fina BioSolutions LLC for drinks and hors d'oeuvres at our Vaccine Development Networking Event!
This content isn’t available here
Access this content and more in the LinkedIn app
-
Rampant Stupidity. The 2017 Trump "tax cut" eliminated the ability to expense R&D costs immediately. Instead, R&D expenses need to be amortized over 5 yrs. Example: If you received $1 million SBIR grant money in 2022, you would owe taxes on ~$800,000, even if you had spent all the money. In FinaBio's case, our 2022 profit went down as we reinvested our earnings but under the new law, our 2022 taxable income was four times higher. I don't know why research companies and Associations haven't been screaming about this. BIO finally put out a plea: Congress still has time to undo an ill-advised 2017 provision that threatens to put small biotech firms out of business. What legislation? The 2017 Tax Cuts and Jobs Act eliminated full tax deductions for R&D costs, amortizing expenses over five years starting with tax returns for 2022. R&D spending that was once 100% deductible became only partially deductible each year. Why it matters: Small, innovative biotechs essential to drug discovery may be unable to operate if taxed for grants or other funding, as BIO explained in a letter to Congress. A solution: Legislation reintroduced in Congress earlier this year, and supported by BIO, would reinstate the deduction. What’s next: There is still time for Congress to pass the legislation this year. BIO, Sarnoff, and Panetta urge action.
-
Likewise, it was wonderful to meet with Andres. Frankly, in our earlier interactions online, he seemed like an overly persistent sales rep but as soon as I met him at the door of #FinaBio, I realized I was wrong. He is an interesting & enthusiastic person. We could easily have talked the whole afternoon away. Among the topics discussed was the status of biotech in South America and he connected me with a an entrepreneur who, coincidentally will be in Boston for #BPI this week and in Maryland next week to visit me. I look forward Andres his next visit.
Passionate about traveling and science. Business Development/Sales Manager - Strong Foundations in business and life science. 18 years of sales experience in the life science industry.
During my visit to Maryland this week, I had the honor to get together with Andrew Lees, Ph.D. @ Fina BioSolutions LLC. He is one of the most passionate and dedicated people I have ever known. Not to mention, how humble, fun, and friendly he is. He is an outstanding scientist who truly believes that vaccines development should be more accessible and affordable. Having a cup of coffee of coffee with him and listening to some of his amazing stories, is just a privilege I wish everyone could have. Thank you Andy for having over at Fina BioSolutions and spending some time with me. You are a perfect example that science and business always have an human element.
-
-
The 2023 Developing Countries Vaccine Manufacturing Network(#DCVMN) meeting is Sept 19-21. I'm warming up my wings for the long flight to Capetown, South Africa. The 2022 event was a wonderful opportunity to meet colleagues from around the world. With the effort to advance vaccine manufacturing in Africa at the forefront, the 2023 meeting will be interesting. If you are attending and would like to set up a meeting about conjugate vaccine technology, CRM197 and how #FinaBio can assist, please message me.
-